BOCA RATON, Fla.--(BUSINESS WIRE)--The clinical study of the iGrow® Hair Growth System titled “The growth of human scalp hair in females using visible red light laser and LED sources” is featured in the October 2014 issue of Lasers in Surgery and Medicine, considered the gold standard journal on laser-based technology. The study, led by Raymond J. Lanzafame, M.D., M.B.A., F.A.C.S., a board-certified surgeon and expert in laser applications and laser research, demonstrated the clinical efficacy and safety of the iGrow Hair Growth System’s low-level laser therapy (LLLT) to promote hair growth in women.
The iGrow Hair Growth System, developed by Apira Science, Inc., a pioneer of LLLT for more than a decade, is a highly effective, hands-free LLLT hair growth device. Its patented red light technology treats affected areas of the scalp by energizing unhealthy follicle cells and promoting hair growth. iGrow was recently granted over-the-counter clearance from the FDA for use in males with androgenetic alopecia who have Norwood Hamilton Classifications of IIa to V. The clinical trial for men was recognized as the Best Overall Experimental and Translational Research by the American Society for Laser Medicine & Surgery, Inc. (ASLMS).
The latest clinical study featured in Lasers in Surgery and Medicine proves that the iGrow Hair Growth System is equally effective in women. The controlled trial to define the safety and physiologic effects of LLLT on female hair follicles and surrounding tissue included participants afflicted with varying levels of androgenetic alopecia, with skin phototypes classified as I to IV on the Fitzpatrick scale and with Ludwig Baldness Scale Classifications of I to II.
The study’s 45 female subjects, ranging in age from 18 to 60, were randomly assigned to either the active laser and LED group or the group with a sham, non-emitting device. All participants were given an iGrow wearable system to take home and use four times per week for 25 minutes per session. Participants using the active laser system saw on average a 37 percent increase in hair growth over a 16-week period with no side effects.
“This study supports Dr. Lanzafame’s previous groundbreaking research on the effects of LLLT on hair growth in men, demonstrating that the iGrow Hair Growth System is equally effective and safe for increasing terminal hair counts in women,” said Jeff Braile, President of Medical Products at Apira Science, Inc. “That Lasers in Surgery and Medicine—the most prestigious and widely circulated peer-reviewed scientific journal dedicated to basic and applied aspects of laser therapy and diagnosis—published the paper adds further weight to the study. Evidence of LLLT’s superior clinical efficacy and safety continues to grow stronger—both males and females saw no side effects after using the iGrow Hair Growth System while experiencing a significant increase in terminal hair counts.”
For more information on the iGrow Hair Growth System, visit www.igrowlaser.com.
About Apira Science, Inc.
Apira Science, Inc. has pioneered low-level light therapy (LLLT) for over a decade. Its iGrow Hair Growth Platform draws on its expertise and innovations in the application of LLLT to deliver a simple, safe, and effective hair growth treatment.
iGrow is a registered trademark of Apira Science, Inc.